Gerresheimer Surges Past 27 Euros as GLP-1 Tailwinds Fuel MDAX-Leading Rally

Gerresheimer jumps 6% on Thursday, breaking above its 200-day moving average, as GLP-1 drug demand fuels a 24% monthly gain. However, the stock remains 55% below its year-ago high with extreme 67% volatility.

Gerresheimer posted a near-6% gain on Thursday, closing at 27.12 euros, even as the DAX slipped 0.53% on geopolitical jitters and rising bond yields. The move stood out — not just because it defied a down day for the blue-chip index, but because it capped a month of unusually strong momentum. Over the past 30 days, the specialty packaging group has added more than 24%, making it the best performer in the MDAX.

The jump across the 27-euro mark carried technical weight. Gerresheimer’s 200-day moving average hovers around 27 euros, a level that trend-followers watch closely. Hitting that zone after a prolonged slide signals that the short-term recovery may have legs — provided the underlying drivers hold up.

At the heart of the rally lies the GLP-1 boom. Demand for blockbuster diabetes and weight-loss drugs like Ozempic and Wegovy has cascaded into orders for Gerresheimer’s injection systems and autoinjectors. Big pharma contracts are scaling up, and the company has raised its guidance, drawing in institutional investors who see the production capacity build-out as credible.

Still, the long-term chart tells a more sobering story. The stock remains roughly 55% below its level a year ago, and the 52-week high of 64.40 euros is nearly 58% away. That means the current surge is a rebound from deeply depressed levels, not a new uptrend — at least not yet.

Volatility remains extreme. The annualised 30-day swing stands at 67%, leaving the stock vulnerable to profit-taking at the first whiff of bad news. The recent stability in margins and pricing power, which the market cheered on Thursday, will face its next test when quarterly results land. For now, the narrative is that after a brutal correction, Gerresheimer is finding a floor — but the path back to previous highs will require sustained execution and no further shocks from the pharmaceutical supply chain.

The broader MDAX momentum story also helped lift peers like Sartorius, which added over 4% on Thursday, underscoring that the pharma-adjacent sector is drawing buyers again. But Gerresheimer’s 30-day advance of 24% outpaces every other mid-cap name, from Salzgitter’s 8% to Norma’s 14%. The question for investors is whether this is the start of a sustained re-rating or simply a sharp bounce in a long-term decline.